Resistance to COVID-19 drug detected in lab study

Vanderbilt research shows that the virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.  

COVID treatment studied by VUMC gains FDA approval

Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Posing with the award presented by the Tennessee Hospital Association are (front row, from left) Molly Knostman, PharmD, MHA, C. Wright Pinson, MBA, MD, Patty Wright, MD, Mark Sullivan, PharmD (back row, from left) Halden Van Cleave, PharmD, MS, Deidra Dickerson, PharmD, Garrett Crothers, PharmD, Kevin Scharfman, PharmD, Eric Patton and Ryan Schell, PharmD.

THA honors VUMC efforts in remdesivir distribution

A team of pharmacists and physicians from Vanderbilt University Medical Center that this spring took on statewide distribution of remdesivir, an urgently needed investigational drug for severely ill patients hospitalized with COVID-19, has received the President’s Award from the Tennessee Hospital Association (THA).

New data offer insights on COVID treatments for people with cancer

Newly released data on treatment outcomes of people with cancer diagnosed with COVID-19 reveal a racial disparity in access to Remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite effect in the general patient population.

New study supports remdesivir as COVID-19 treatment

This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

Remdesivir helps reduce COVID-19 recovery time: study

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.